Therapieführung Und/oder Therapieüberwachung für eine Behandlung mit Angiotensin-Rezeptor-Agonist Und/oder einem Vorläufer davon

Details

Veröffentlichungs-Nr.

EP4768915

Anmeldetag

20. Dezember 2019

Veröffentlichung

1. Juli 2026

Rechtsraum

EP

IPC

G01N33/547

Abstract

Subject matter of the present invention is an angiotensin-receptor-agonist and/ or a precursor thereof for use in the treatment of a disease in a subject, • wherein said disease is selected from the group comprising heart failure, chronic heart failure, acute heart failure (AHF), myocardial infarction (MI), stroke, liver failure, burn injuries, traumatic injuries, severe infection (microbial, viral (e.g. AIDS), parasitic diseases (e.g. Malaria)), SIRS or sepsis, cancer, acute kidney injury (AKI), CNS disorders (e.g. seizures, neurodegenerative diseases), autoimmune diseases, vascular diseases, hypotension and shock, and • wherein said subject has an amount of DPP3 protein and/or DPP3 activity in a sample of bodily fluid that is above a predetermined threshold.

Anmelder

Firma

4TEEN4 Pharmaceuticals GmbH

Land

🇩🇪 Deutschland